Compare ADPT & FCF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADPT | FCF |
|---|---|---|
| Founded | 2009 | 1934 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2019 | 1994 |
| Metric | ADPT | FCF |
|---|---|---|
| Price | $14.25 | $18.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | $17.78 | ★ $19.75 |
| AVG Volume (30 Days) | ★ 1.4M | 669.0K |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 2.94% |
| EPS Growth | ★ 63.89 | 5.76 |
| EPS | N/A | ★ 1.47 |
| Revenue | ★ $276,976,000.00 | N/A |
| Revenue This Year | $3.98 | $16.32 |
| Revenue Next Year | $22.72 | $6.25 |
| P/E Ratio | ★ N/A | $12.52 |
| Revenue Growth | ★ 54.77 | N/A |
| 52 Week Low | $8.38 | $15.00 |
| 52 Week High | $20.76 | $19.14 |
| Indicator | ADPT | FCF |
|---|---|---|
| Relative Strength Index (RSI) | 50.46 | 53.97 |
| Support Level | $12.22 | $18.28 |
| Resistance Level | $15.38 | $19.06 |
| Average True Range (ATR) | 0.62 | 0.35 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 50.26 | 35.42 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
First Commonwealth Financial Corp functions in the financial services sector in the United States. Through its subsidiary, it offers a range of consumer and commercial banking services such as personal checking accounts, interest-earning checking accounts, savings accounts, insured money market accounts, investment certificates, fixed & variable rate certificates of deposit, and various kinds of loans. It also provides trust and wealth management services and offers insurance products. The company earns the majority of its revenue through net interest income.